Sagimet Biosciences to Participate in Two Upcoming Investor Conferences
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT), a clinical-stage biopharmaceutical company focused on developing therapeutics for metabolic and fibrotic pathways, has announced its participation in two upcoming investor conferences in September 2025.
The company will present at the Cantor Global Healthcare Conference on September 3, featuring a fireside chat at 1:35 p.m. ET, and the H.C. Wainwright 27th Annual Global Investment Conference on September 9. A webcast of the Cantor presentation will be available on Sagimet's website for 90 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction – SGMT
On the day this news was published, SGMT declined 0.14%, reflecting a mild negative market reaction. Argus tracked a peak move of +6.0% during that session. Our momentum scanner triggered 23 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $439K from the company's valuation, bringing the market cap to $313M at that time.
Data tracked by StockTitan Argus on the day of publication.
SAN MATEO, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in two upcoming investor conferences.
- Cantor Global Healthcare Conference in New York on September 3, 2025, with a fireside chat at 1:35 p.m. ET / 10:35 a.m. PT; and
- H.C. Wainwright 27th Annual Global Investment Conference in New York on September 9, 2025.
A webcast of the Cantor fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Sagimet’s lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). FASCINATE-2, a Phase 2b clinical trial of denifanstat in MASH with liver biopsy-based primary endpoints, was successfully completed with positive results. Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis), and end-of-Phase 2 interactions with the FDA have been successfully completed, supporting the advancement of denifanstat into further development. Sagimet has recently initiated a Phase 1 first-in-human clinical trial with a second oral FASN inhibitor drug candidate, TVB-3567, that is planned to be developed for acne in the U.S. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Michael Fitzhugh
LifeSci Advisors
mfitzhugh@lifescicomms.com
FAQ
When is Sagimet Biosciences (SGMT) presenting at the Cantor Global Healthcare Conference?
Where can I watch Sagimet Biosciences' (SGMT) Cantor Conference presentation?
Which investor conferences is Sagimet Biosciences (SGMT) attending in September 2025?
What type of company is Sagimet Biosciences (SGMT)?
